证券代码：000963 证券简称：华东医药 公告编号：2025-108 华东医药股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会。 2、股东会的召集人：公司董事会 公司于 2025 年 11 月 20 日召开的第十一届董事会第五次会议审 议通过了《关于召开 2025 年第二次临时股东会的议案》，决定召开 2025 年第二次临时股东会。 3、会议召开的合法、合规性：本次会议的召集、召开符合《中 华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 09 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的 具体时间为 2025 年 12 月 09 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳 ...

华东医药股份有限公司 董事会薪酬与考核委员会 关于公司 2022 年限制性股票激励计划相关事项的核查意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《深 圳证券交易所股票上市规则》《上市公司股权激励管理办法》等法律 法规、规范性文件的规定，华东医药股份有限公司（以下简称"公司"） 董事会薪酬与考核委员会于2025年11月20日召开了第十一届董事会 薪酬与考核委员会2025年第二次会议，审议通过了《关于2022年限制 性股票激励计划首次授予限制性股票第三个解除限售期解除限售条 件成就的议案》《关于调整2022年限制性股票激励计划回购价格的议 案》《关于回购注销部分限制性股票的议案》，对公司2022年限制性 股票激励计划相关事项进行了核查，现发表核查意见如下： 一、董事会薪酬与考核委员会对2022年限制性股票激励计划首次 授予限制性股票第三个解除限售期解除限售条件成就的核查意见 公司2022年限制性股票激励计划首次授予限制性股票第三个解 除限售期解除限售条件成就的核查结果如下： | 解除限售条件 | 是否满足解除限售条件的说明 | | --- | --- | | 公司未发生以下任一情形： 1、最近一个会 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-103 华东医药股份有限公司 第十一届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华东医药股份有限公司（以下简称"公司"）第十一届董事会第五 次会议的通知于2025年11月17日以书面和电子邮件等方式送达各位 董事，于2025年11月20日（星期四）在公司会议室以现场并结合通讯 方式召开。会议应参加董事11名，实际参加董事11名。会议由公司董 事长主持。会议的召开和表决程序符合《公司法》《公司章程》的有 关规定，会议合法有效。 二、董事会会议审议情况 董事会就以下议案进行了审议，经书面和通讯方式表决，通过决 议如下： 1、审议通过《关于2022年限制性股票激励计划首次授予限制性 股票第三个解除限售期解除限售条件成就的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn） 的公司《关于2022年限制性股票激励计划首次授予限制性股票第三个 解除限售期解除限售条件成就的公告》。 关联董事吕梁、朱亮回避表决。 表决结果：9票 ...

Core Viewpoint - Huadong Medicine's stock price has experienced fluctuations, with a year-to-date increase of 19.81% but a recent decline of 6.51% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Huadong Medicine achieved a revenue of 32.664 billion yuan, representing a year-on-year growth of 3.77%, and a net profit attributable to shareholders of 2.748 billion yuan, up 7.24% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of Huadong Medicine's shareholders decreased by 1.50% to 68,800, while the average circulating shares per person increased by 1.53% to 25,466 shares [2] - The company has distributed a total of 8.873 billion yuan in dividends since its A-share listing, with 3.771 billion yuan distributed over the past three years [3] Stockholder Composition - The top circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 12.1653 million shares to 52.0036 million shares [3] - China Securities Finance Corporation maintained its position as the fourth-largest shareholder with 22.1868 million shares, while other notable shareholders saw reductions in their holdings [3] Business Overview - Huadong Medicine, established on March 31, 1993, and listed on January 27, 2000, is primarily engaged in the production and sale of various pharmaceutical products, with a revenue composition of 64.45% from commercial activities and 39.69% from manufacturing [1] - The company operates in several sectors, including vitamins, traditional Chinese medicine, hepatitis treatment, pharmaceutical e-commerce, and medical aesthetics [1]

Core Insights - AbbVie reported global net revenue of ELAHERE at $508 million for the first three quarters of 2025, with $453 million coming from the U.S. market [2] - Huadong Medicine announced that ELAHERE's packaging version for the Chinese market was officially commercialized earlier this month, with the first prescription issued nationwide [2] - ELAHERE has achieved sales revenue exceeding 45 million yuan in the Greater China region from January to September 2025 [2]

Group 1 - The company is currently in communication with its partner regarding the supply timeline for "Yanduo" [2] - The supply schedule for "Yanduo" remains uncertain due to the partner's reasons [2] - The company is actively working to push forward the related matters with the partner [2]

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]

Core Insights - Jiangxi Yunfentu Technology Co., Ltd. has been established with a registered capital of 36.9 million RMB, focusing on artificial intelligence and cloud computing services [1][2][4] - The company is wholly owned by East China Pharmaceutical Co., Ltd. [1][4] Company Information - Legal representative: Liu Gangjun [2] - Registration status: Active [2] - Establishment date: November 17, 2025 [2] - Unified social credit code: 91360125MAK2106L09 [2] - Business scope includes AI technology platform, software development, cloud computing services, data processing, and information system integration [1][2] Shareholder Information - East China Pharmaceutical Co., Ltd. holds 100% of the shares in Jiangxi Yunfentu Technology Co., Ltd. [4]

Core Viewpoint - East China Pharmaceutical has established a new company, Jiangxi Yunfentu Technology Co., Ltd., focusing on artificial intelligence and Internet of Things (IoT) businesses [1] Group 1: Company Overview - Jiangxi Yunfentu Technology Co., Ltd. is wholly owned by East China Pharmaceutical [1] - The company's business scope includes artificial intelligence foundational resources and technology platforms, AI public service platform technical consulting, AI application software development, IoT technology research and development, and IoT technology services [1]

Core Viewpoint - The announcement highlights that Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the conversion of the conditional approval of the drug Mirvetuximab Soravtansine Injection (ELAHERE) to regular approval, marking a significant milestone in the drug's development process [1][4][9]. Drug Information - The drug is known as Mirvetuximab Soravtansine Injection, with a specification of 100 mg (20 mL) per bottle, and is classified as a Class 3.1 therapeutic biological product [1][5]. - It is indicated for adult patients with platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have previously received 1-3 lines of systemic therapy and are positive for folate receptor alpha (FRα) [1][4]. Development and Approval History - The drug was developed in collaboration with ImmunoGen, Inc., which is now acquired by AbbVie, and is the first and only approved antibody-drug conjugate (ADC) targeting FRα for treating platinum-resistant ovarian cancer in China, the U.S., and the EU [5][6]. - The drug received accelerated approval from the U.S. FDA in November 2022 and full approval in March 2024, with subsequent approvals in the EU in November 2024 [6][7]. Clinical Trial Results - The approval for the regular application was based on the results of the Phase III clinical trial MIRASOL, which demonstrated a 35% reduction in the risk of tumor progression or death (HR 0.65, p<0.0001) and a 33% reduction in the risk of death (HR 0.67, p=0.0046) compared to the control group [7]. - The trial also indicated that the treatment group experienced fewer severe adverse events and lower rates of treatment discontinuation [7]. Market Performance and Sales - The drug has been actively marketed in China, with sales exceeding 45 million yuan from January to September 2025, and it has been successfully launched in several hospitals [8][9]. - AbbVie reported global net revenue of $508 million for ELAHERE in the first three quarters of 2025, with $453 million coming from the U.S. market [8].